EDGC is the international joint venture established in 2013 between EONE Laboratories and Diagnomics, listed on KOSDAQ in 2018. EDGC has developed leading-edge technology for genome analysis through constant research and development and has established business network to expand its influence to the global market.Because of that, EDGC diagnoses various diseases over the entire life cycle and provides clinical solution for precision and personalized medicine. Also, EDGC has acquired international and domestic certificates to provide reliable services to customers, i.e. CLIA, CAP, CE. ISO13485 etc.Furthermore, as the global leader of genome business, EDGC has worked on global projects with the most influential Bio-Tech and IT companies in the world such as Illumina and Microsoft. In addition, EDGC is participating as the ONLY Asian partner of the Global Screening Array Consortium in which only 12 other global leading companies participate in.EDGC has enhanced its competitiveness through the persistent business expansion. Such as the application of genetic testing for diagnosing, predicting and preventing diseases over the entire life cycle, as well as direct-to-consumer (DTC) services and DNA application development. EDGC established business by creating an entire ecosystem based on the genome analysis and has applied each genetic characterization for a personalized lifestyle.Finally, EDGC will become the company creating healthy and happy life and better future for the people.